Home Pitango partner talks new $175M health tech fund, AI, and ro... Last week, Israel’s Pitango VC announced the closing of its second healthcare-focused fund, Pitango HealthTech II.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.